Empagliflozin Has Similar Efficacy Across Subgroups, More Data Needed in CKD: Dr Jennifer Green
November 26th 2022Data on empagliflozin in chronic kidney disease (CKD) showed the drug had similar efficacy across subgroups, but more data is needed to really understand the benefit of the drug in CKD, said Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator.
Read More
Daniel E. Weiner, MD, MS, board certified nephrologist and lead navigator at Tufts Clinical and Translational Science Institute, spoke on the limitations and future potential of value-based payment systems for chronic kidney disease (CKD), including the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model and the Kidney Care Choices (KCC) Models.
Read More
Curtis Warfield, MS, senior quality analyst, Indiana State Department of Health, and regional leader of National Kidney Foundation's Kidney Advocacy Committee, spoke on limitations regarding the current process of educating and managing lifestyle interventions for patients with chronic kidney disease (CKD), and how nephrologists can better integrate these strategies.
Read More
Nephrology Director Shares Ups, Downs of Participating in Kidney Care First
November 6th 2022It has been 3 years since new kidney care payment models were announced by HHS, and at a session at Kidney Week 2022, the associate division director of nephrology at the University of Alabama at Birmingham described his organization’s participation in Kidney Care First, one of the value-based care models announced in 2019.
Read More
Jen Gunter, MD, obstetrician and gynecologist, author, and specialist in chronic pain medicine and vulvovaginal disorders, spoke on the change in perspective regarding the medical and scientific community's role in dispelling health care misinformation on social media and in the press.
Read More
Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator, discussed findings of the EMPA-KIDNEY trial presented at Kidney Week 2022, which showed a 28% improvement for patients with chronic kidney disease (CKD) on empagliflozin, whether in reduced mortality from cardiovascular disease or progression of CKD.
Read More
Dr Ray Bignall II on Understanding the Environment Patients Live In
November 4th 2022Access to care remains a key issue when trying to deliver equitable kidney health care to patients, explained O.N. Ray Bignall II, MD, assistant chief diversity and health equity officer at Nationwide Children’s Hospital.
Read More
Dr Brent W. Miller on Emerging Technologies in Home Dialysis and Strategies to Improve Uptake
November 4th 2022Brent W. Miller, MD, board certified nephrologist and professor of clinical medicine at Indiana University School of Medicine, discussed new and emerging technologies for at-home hemodialysis and peritoneal dialysis, as well as efforts that have been made to address uptake issues for patients with kidney disease.
Read More
Empagliflozin Cuts Risk of Cardiovascular Death, More Severe CKD by 28%, Study Finds
November 4th 2022Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduced the risk of death or worsening progression of chronic kidney disease (CKD) by 28%, according to results published Friday at Kidney Week 2022.
Read More
As Medical Falsehoods Persist, Concerns About Future Pandemic Readiness Grow
November 3rd 2022Physicians and scientists are worried about the future pandemic preparedness, and the reasons why are largely due to social and political influences, according to a keynote speech and panel discussion on the first day of Kidney Week 2022.
Read More
Susan E. Quaggin, MD, FASN, president of the American Society of Nephrology (ASN) for the 2021-2022 term, discussed the major focuses and breakthroughs in nephrology to be presented at Kidney Week 2022, which include novel treatments for common and rare kidney diseases, as well as efforts to address disparities for transplant and care access.
Read More
Dr George Bakris Compares FIDELIO-DKD Renal Outcomes With Those of SGLT2 Inhibitor Trials
October 27th 2020Although their underlying mechanisms differ, finerenone reduces albuminuria to the same extent as SGLT2 inhibitors, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.
Read More
Dr Shweta Bansal Explains Factors Associated With Increased Screening, Recognition of CKD
October 26th 2020Recognizing chronic kidney disease (CKD) can lead to earlier implementation of interventions among patients, ultimately reducing the risk of end stage renal disease, said Shweta Bansal, MD, FASN, associate professor of medicine in the nephrology division at the University of Texas Health Center at San Antonio.
Read More
Dr Kunihiro Matsushita Discusses Alternative End Points for Clinical Trials on Kidney Disease
October 26th 2020Although renal replacement therapy is a clinically meaningful end point, trials must include numerous patients and follow them for long periods of time, said Kunihiro Matsushita, MD, an associate professor in the Department of Epidemiology and Division of Cardiology at Johns Hopkins University.
Read More
COVID-19, AKI, and ESRD Research Roundup
October 25th 2020During Kidney Week, various studies discussed not only the effect coronavirus disease 2019 (COVID-19) has on patients with end-stage renal disease (ESRD) but also new attacks of acute kidney injury (AKI) that can cause severe illness or even death.
Read More
Flawed Racial Assumptions in eGFR Have Care Implications in CKD
October 25th 2020The use of estimated glomerular filtration rate (eGFR) equations in assessing chronic kidney disease (CKD) for Black patients may lead to underdiagnosis and undertreatment, according to a nephrologist speaking at Kidney Week.
Read More
Dr Joshua Rein Offers Insights on Cannabis Use for Chronic Kidney Disease
October 25th 2020Several symptoms patients with chronic kidney disease (CKD) experience are approved indications for medical cannabis, said Joshua L Rein, DO, FASN, a nephrologist at Mt. Sinai Hospital in New York City.
Read More
Racial Disparities in Acute Care Utilization Rates Among Children With Glomerular Disease
October 24th 2020In reviewing the previous literature on health disparities in kidney disease, there is not a lot described in patients with kidney pathologies outside of ESKD and dialysis, said Jill Krissberg, MD, a pediatric nephrology fellow at Stanford University School of Medicine.
Read More
Researchers Use GWAS to Identify Novel Loci Associated with Kidney Function
October 24th 2020After conducting further genome-wide association studies (GWAS), we will be able to inform communities about the potential implications of gene expression in their kidneys, said Adriana Hung, MD, MPH, associate professor of medicine at Vanderbilt University in an interview with Bryce Rowan, a statistical genetic analyst.
Read More
Roxadustat Lowers LDL in Patients With CKD, Anemia
October 24th 2020Additional studies about roxadustat, a drug in the new class of hypoxia-inducible factor stabilizers, were released during Kidney Week; one of them explored its role in lowering cholesterol in patients with chronic kidney disease (CKD) and anemia.
Read More
Dr Benjamin Griffin Identifies Risk Factors Associated With Hospital Readmission Following AKI
October 24th 2020People who experience acute kidney injuries (AKIs) in the hospital have higher rates of cardiac disease and death compared with those who have been discharged, said Benjamin Griffin, MD, a nephrologist and assistant professor of internal medicine at the University of Iowa.
Read More